伯瑞替尼对比谷美替尼治疗间质-上皮细胞转化因子突变的局部晚期或转移性非小细胞肺癌的成本-效果分析
谢勇萍, 谢国凤, 卜灿, 程芳
Cost-effectiveness analysis of vebreltinib versus gumarontinib in first-line treatment of locally advanced or metastatic NSCLC with MET exon 14 skipping mutation
XIE Yongping, XIE Guofeng, BU Can, CHENG Fang
中国医院药学杂志
.
2026, (8): 930
-936
.
DOI: 10.13286/j.1001-5213.2026.08.11
